Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Midtlien

Clinical Nurse Specialist, Adult Health Dayton, OH Clinical Nurse Specialist

NPI 1639489545 CMS profile 11025354

5300 Far Hills Ave, Dayton, OH 45429

Open in the dashboard

General payments

$6,271

302 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Midtlien of Dayton, OH is reported in the CMS Open Payments database as having received $6,271 across 302 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,312 78
2024 General $1,084 58
2023 General $1,374 70
2022 General $893 54
2021 General $1,607 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Midtlien
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Jennifer Midtlien were reported at $1,312. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Jennifer Midtlien Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,607 $133 $48–$445 $132
2022 $893 $163 $57–$526 $149
2023 $1,374 $173 $64–$597 $160
2024 $1,084 $171 $54–$575 $164
2025 $1,312 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,267 99 payments
  2. EPI Health, LLC $1,017 2 payments
  3. Janssen Biotech, Inc. $442 27 payments
  4. Lilly USA, LLC $336 17 payments
  5. Novartis Pharmaceuticals Corporation $313 16 payments
  6. Incyte Corporation $275 13 payments
  7. E.R. Squibb & Sons, L.L.C. $258 12 payments
  8. UCB, Inc. $245 11 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $236 11 payments
  10. Genzyme Corporation $232 9 payments
  11. Other $1,650 85 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,090 298 payments
  2. Honoraria $1,000 1 payment
  3. Education $181 3 payments
Products named General payments · program years 2021–2025
  1. RHOFADE $1,017 2 payments
  2. WYNZORA $1,017 2 payments
  3. MINOLIRA EXTENDED RELEASE Dermatology $1,017 2 payments
  4. MINOLIRA EXTENDED RELEASE Dermatology $1,017 2 payments
  5. CLODERM $1,017 2 payments
  6. SKYRIZI $743 62 payments
  7. RINVOQ $458 31 payments
  8. TREMFYA $408 19 payments
  9. TALTZ $336 17 payments
  10. COSENTYX $313 16 payments
  11. Other $3,921 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,313

Median for Nurse Practitioner: 389

Drug cost

$294,625

Median for Nurse Practitioner: $21,885

Branded share of claims

10.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 40 $148,848
Humira(Cf) Adalimumab Brand 11 $74,517
Dupixent Syringe Dupilumab Brand 13 $46,270
Clobetasol Propionate Generic 145 $4,077
Fluorouracil Generic 45 $3,960
Ketoconazole Generic 366 $3,845
Tacrolimus Generic 15 $2,480
Metronidazole Generic 38 $1,972
Triamcinolone Acetonide Generic 213 $1,528
Imiquimod Generic 36 $1,076

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$99,832

Of which drugs: $3,618

Medicare patients

589

Average age 75

Services billed

3,206

343 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Diabetes 26%
Ischemic heart disease 26%
Depression 20%
Chronic kidney disease 18%
Atrial fibrillation 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 12 12 $3,586
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 42 $32

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $200
$200 — —
RINVOQ
  • AbbVie, Inc. $129
$129 — —
SPEVIGO
  • Boehringer Ingelheim Pharmaceuticals, Inc. $78
$78 — —
TALTZ
  • Lilly USA, LLC $75
$75 — —
OPZELURA
  • Incyte Corporation $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

302 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record